Interstitial lung disease

European Respiratory Review

Volumn 22, Issue 127, 2013, Pages 26-32

  Cottin, Vincent ^a,b  

^a LOUIS PRADEL HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Clinical trial; Connective tissue disease; Exacerbation; Idiopathic pulmonary fibrosis; Prognosis; Sarcoidosis

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MACITENTAN; NINTEDANIB; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ANOREXIA; ANTICOAGULANT THERAPY; AUSTRIA; AUTOIMMUNE DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LONG TERM CARE; LUNG BIOPSY; LUNG CAPACITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PREDICTION; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SARCOIDOSIS; SURVIVAL; SYMPTOMATOLOGY; VOMITING;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; LUNG DISEASES, INTERSTITIAL; RESPIRATORY SYSTEM AGENTS; RISK FACTORS; SARCOIDOSIS, PULMONARY; TREATMENT OUTCOME;

EID: 84874746236     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00006812     Document Type: Review

References (63)

1. Cottin V. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur Respir Rev 2012; 21: 161-167.
2. Wuyts WA, Agostini C, Antoniou K, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 2012; [Epub ahead of print DOI: 10.1183/09031936.00073012].
3. Gunther A, Korfei M, Mahavadi P, et al. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 152-160.
4. Margaritopoulos GA, Romagnoli M, Poletti V, et al. Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis. Eur Respir Rev 2012; 21: 48-56.
5. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
6. du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 141-146.
7. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
8. Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
9. Demedts M, Behr J, Buhl R, et al. IFIGENIa: effects of Nacetylcysteine (NAC) on primary end points VC and DLCO. Eur Respir J 2004; 24: Suppl. 48, 668.
10. Wells AU, Behr J, Costabel U, et al. Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. Eur Respir J 2012; 39: 805-806.
11. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (capacity): two randomised trials. Lancet 2011; 377: 1760-1769.
12. Richeldi L. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 147-151.
13. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; 9: CD003134.
14. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
15. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
16. Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J 2012; 39: 125-132.
17. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008; 153: Suppl. 1, S367-S378.
18. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.
19. Raghu G. Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012. Lancet 2012; 380: 699-701.
20. King TE Jr, Behr J, Brown KK, et al. Build-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
21. King TE Jr, Brown KK, Raghu G, et al. Build-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
22. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-628.
23. Muller-Quernheim J, Wells A. Evidence-based recommendations in idiopathic pulmonary fibrosis: a year is a long time in interstitial lung disease. Am J Respir Crit Care Med 2012; 186: 5-7.
24. Vancheri C, du Bois RM. Progression-free end point for idiopathic pulmonary fibrosis trials: lessons from cancer. Eur Respir J 2012; [Epub ahead of print DOI: 10.1183/09031936.00115112].
25. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185: 1044-1048.
26. Wells AU, Behr J, Costabel U, et al. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax 2012; 67: 938-940.
27. du Bois RM, Nathan SD, Richeldi L, et al. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 2012; 186: 712-715.
28. Nathan SD, du Bois RM. Idiopathic pulmonary fibrosis trials: recommendations for the jury. Eur Respir J 2011; 38: 1002-1004.
29. Albera C. Challenges in idiopathic pulmonary fibrosis trials: the point on end-points. Eur Respir Rev 2011; 20: 195-200.
30. Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011; 184: 842-847.
31. Lederer DJ. Secondary prevention of idiopathic pulmonary fibrosis: catching the horse still in the barn. Am J Respir Crit Care Med 2012; 185: 697-699.
32. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012; 185: 1147-1153.
33. Cottin V, Cordier JF. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012; 40: 519-521.
34. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012; 40: 101-109.
35. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-969.
36. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
37. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
38. Hook JL, Arcasoy SM, Zemmel D, et al. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 359-365.
39. Judge EP, Fabre A, Adamali HI, et al. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012; 40: 93-100.
40. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37: 356-363.
41. Morawiec E, Tillie-Leblond I, Pansini V, et al. Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses. Eur Respir J 2011; 38: 1487-1489.
42. Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 352-358.
43. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-643.
44. Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector ct in patients with idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 344-351.
45. Raghu G, Meyer KC. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? Eur Respir J 2012; 39: 242-245.
46. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 1390-1394.
47. Girgis RE, Gugnani MK, Abrams J, et al. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. Am J Respir Crit Care Med 2002; 165: 1587-1591.
48. Tiev KP, Cabane J, Aubourg F, et al. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J 2007; 30: 26-30.
49. Tiev KP, Hua-Huy T, Kettaneh A, et al. Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma. Thorax 2012; 67: 157-163.
50. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1322-1328.
51. Navaratnam V, Ali N, Smith CJ, et al. Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis? Respir Med 2011; 105: 1925-1930.
52. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176: 691-697.
53. Fischer A, West SG, Swigris JJ, et al. Connective tissue diseaseassociated interstitial lung disease: a call for clarification. Chest 2010; 138: 251-256.
54. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011; 140: 1292-1299.
55. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
56. Corte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39: 661-668.
57. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999; 17: 615-620.
58. Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with antiCCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012; 106: 1040-1047.
59. Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008; 31: 372-379.
60. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52: 525-533.
61. Varron L, Cottin V, Schott AM, et al. Late-onset sarcoidosis. Medicine 2012; 91: 137-143.
62. Nardi A, Brillet PY, Letoumelin P, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011; 38: 1368-1373.
63. Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the united states from 1988 to 2007. Am J Respir Crit Care Med 2011; 183: 1524-1530.